Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

Fintel reports that on September 27, 2024, Cantor Fitzgerald initiated coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...